NCT02487290View on ClinicalTrials.gov

ANEUFIX for Endoleaks Type II

NACompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 26, 2018

Primary Completion Date

February 1, 2019

Study Completion Date

December 15, 2020

Conditions
Abdominal Aortic Aneurysm
Interventions
DEVICE

Aneufix ACP-T5

The ACP-T5 is injected via translumbar approach into the aneurysm sac near the entrance/exit of bloodvessel. ACP-T5 will cure and block the endoleak.

Trial Locations (2)

2512

Medisch Centrum Westeinde, The Hague

2035 RC

Spaarne Gasthuisberg, Haarlem

All Listed Sponsors
collaborator

Fakkel bvba

INDUSTRY

lead

TripleMed B.V.

INDUSTRY

NCT02487290 - ANEUFIX for Endoleaks Type II | Biotech Hunter | Biotech Hunter